Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
- 03/12/2025
|
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m.
- 01/30/2025
|
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
- The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
- 01/13/2025
|
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
- Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year.
- 12/19/2024
|
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
- Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
- 12/02/2024
|
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright George Farmer - Scotiabank Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.
- 11/13/2024
|
Adaptimmune Reports Q3 2024 Financial and Business Updates
- Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16 Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patients Planned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million in aggregate cost savings over the next four years enables company to target an operating breakeven during 2027 At the end of Q3, Adaptimmune had Total Liquidity1 of $186.1 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the third quarter ended September 30, 2024. The Company will host a live webcast at 4:30 p.m.
- 11/13/2024
|
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
- 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025 Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) - register here Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced data from the primary analysis of its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in people with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who received previous anthracycline-based therapy.
- 11/13/2024
|
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39 th annual meeting, November 6-10, Houston, TX Podium presentation: "Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma" / Jo Brewer, PhD, Chief Scientific Officer, Adaptimmune.
- 11/05/2024
|
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m.
- 10/31/2024
|
Adaptimmune to Participate in Two Bank Conferences this September
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September. Wells Fargo Healthcare Conference, Boston, MA Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.
- 08/28/2024
|
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Joanna Brewer - Chief Scientific Officer Dennis Williams - Senior Vice President, Late Stage Development John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Matthew Cowper - Leerink Partners Paul Jeng - Guggenheim Securities Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities George Farmer - Scotiabank Arthur He - H.C. Wainwright Kuan-Hung Lin - Wells Fargo Michael Kim - Zacks Small-Cap Research Alexandre Bouilloux - Barclays Operator Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call.
- 08/12/2024
|
Adaptimmune Reports Q2 2024 Financial and Business Updates
- Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders At the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m.
- 08/12/2024
|
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the second quarter ended June 30, 2024, before the US markets open on Monday, August 12, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
- 08/05/2024
|
US FDA approves Adaptimmune's gene therapy for rare type of cancer
- The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy.
- 08/02/2024
|
STM Investors Have Opportunity to Join STMicroelectronics N.V. Fraud Investigation with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--STM Investors Have Opportunity to Join STMicroelectronics N.V. Fraud Investigation with the Schall Law Firm.
- 08/01/2024
|
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
- PHILADELPHIA & OXFORD, England--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses.
- 08/01/2024
|
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
- Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.
- 07/03/2024
|
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
- By Michael Kim
- 06/17/2024
|
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
- Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, is presenting data from its pivotal IGNYTE-ESO trial of lete-cel (letetresgene autoleucel), an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual meeting. Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center will present "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" in an oral session at 11:30 a.m.
- 06/03/2024
|
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
- Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
- 05/30/2024
|
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
- Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
- 05/30/2024
|
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis Williams - Head of Late Stage Development Cintia Piccina - Chief Commercial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright Peter Lawson - Barclays Operator Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.
- 05/15/2024
|
Adaptimmune Reports Q1 2024 Financial and Business Updates
- Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCO Cash runway into late 2025 Conference call today at 8 a.m. EDT webcast link HERE Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the first quarter ended March 31, 2024.
- 05/15/2024
|
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
- First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026.
- 05/15/2024
|
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
- Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
- 05/01/2024
|
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
- Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon.
- 04/26/2024
|
Adaptimmune (ADAP) Down on End of Collaboration With Roche
- Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
- 04/15/2024
|
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
- Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entered in 2021, has been terminated. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "We've had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform.
- 04/12/2024
|
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
- Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and translational results from afami-cel's SPEARHEAD-1 trial (NCT04044768).
- 03/27/2024
|
Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Jo Brewer - Chief Scientific Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities Jonathan Chang - Leerink Partners Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's Fourth Quarter and Year-End Conference Call and Business Update. I will now turn the call over to Juli Miller.
- 03/06/2024
|
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
- U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams preparing for product delivery Lete-cel program transitioned back to Adaptimmune and the Company is planning for US commercial launch in 2026 Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million Cash runway into early 2026; with greater than $300 million including current cash on hand, future expected income from partners and projected other non-dilutive capital sources Webcast to be held today, March 6, 2024, at 8:00 a.m. EST. (1:00 p.m.
- 03/06/2024
|
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
- Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023.
- 02/27/2024
|
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
- 02/21/2024
|
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
- If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024.
- 01/31/2024
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
- Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
- 01/16/2024
|
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
- Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024 Company preparing for US launch of afami-cel in 2H 2024 upon expected approval Pivotal trial for lete-cel met its primary endpoint for efficacy; full data set in Q3 2024 Company working toward approval of lete-cel; planning for US commercial launch in 2026 Company funded into early 2026 with > $300 million including existing balance sheet, projected payments from partners, and other non-dilutive capital sources Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 4, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the Company's plans for its emerging sarcoma franchise including projections for peak US sales of up to $400 million. The Company will present plans for the franchise at the JP Morgan Healthcare Conference on January 11th from 8:15 to 8:55 a.m.
- 01/04/2024
|
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
- First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacy Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. Afami-cel is eligible for a Priority Review, which would shorten the FDA's review of the application to 8 months versus a standard review timeline of 12 months.
- 12/06/2023
|
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
- Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.
- 11/30/2023
|
Adaptimmune Receives Transfer of IND for Lete-cel Program
- Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024 Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, announces the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to Adaptimmune for the pivotal IGNYTE-ESO (NCT03967223) clinical trial.
- 11/29/2023
|
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/13/2023
|
Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior Vice President-Late Stage Development Elliot Norry – Chief Medical Officer Jo Brewer – Chief Scientific Officer Gavin Wood – Chief Financial Officer Conference Call Participants Jerry Gong – Mizuho Securities Marc Frahm – TD Cowen Dylan Drakes – Leerink Partners Yanan Zhu – Wells Fargo Securities Peter Lawson – Barclays Operator Good morning, ladies and gentlemen, and welcome to the Adaptimmune's Q3 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms.
- 11/08/2023
|
Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
- The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.60, representing a +1.5% change from its previous close.
- 11/07/2023
|
Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights
- The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close.
- 10/27/2023
|
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
- Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2023, before the US markets open on Wednesday, November 8, 2023. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m.
- 10/25/2023
|
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
- Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m.
- 08/03/2023
|
Buy 5 Top-Ranked Stocks With Rising P/E in July
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).
- 07/06/2023
|
GSK Announces Extension of FDA Review for Rare Blood Therapy
- GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
- 06/19/2023
|
Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP)
- The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 05/30/2023
|
Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Helen Tayton-Martin - Chief Business & Strategy Officer Joanna Brewer - Chief Scientific Officer John Lunger - Chief Patient Supply Officer Conference Call Participants Marc Frahm - TD Cowen Tony Butler - EF Hutton Operator Hello. Welcome to Adaptimmune's First Quarter Call and Business Update.
- 05/12/2023
|
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
- Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Sweetgreen (SG), Adaptimmune Therapeutics (ADAP), Owl Rock Capital (ORCC), MACOM Technology Solutions (MTSI) and Equity Commonwealth (EQC).
- 05/04/2023
|
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
- Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2023, before the US markets open on Friday, May 12, 2023. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m.
- 04/28/2023
|
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
- Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
- 04/12/2023
|
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
- GSK gave Adaptimmune nearly $37 million as part of a rights deal. Adaptimmune said it expects to launch its first marketed therapy, possibly as soon as the end of this year.
- 04/11/2023
|
Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors
- ADAP is down after merging with TCRR, while TCRR is up. The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free.
- 03/26/2023
|
Adaptimmune Therapeutics And TCR² Therapeutics To Merge (ADAP) (TCRR)
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR) announced a plan to merge. These are the details.
- 03/06/2023
|
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
- Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2022, before the US markets open on Monday, March 6, 2023. Following the announcement, the Company will host a live webcast at 8:00 a.m.
- 02/22/2023
|
Adaptimmune: The Afamicel Rolling BLA Is Its Lifeline
- ADAP has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline.
- 12/09/2022
|
5 Penny Stocks To Buy According To Analysts, Targets Up To 353%
- Analysts say these are penny stocks to buy. Do you agree?
- 11/11/2022
|
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
- Positive trial data is powering the biotech's stock higher today.
- 11/08/2022
|
Adaptimmune Therapeutics plc (ADAP) Q3 2022 Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Dennis Williams - Senior Vice President, Late Stage Development Jo Brewer - Chief Scientific Officer Helen Tayton-Martin - Chief Business and Strategy Officer Conference Call Participants Marc Frahm - Cowen & Company Tony Butler - Roth Capital Partners Mara Goldstein - Mizuho Jonathan Chang - SVP Securities Peter Lawson - Barclays Soumit Roy - Jones Trading Operator Hello and welcome to Adaptimmune's Third Quarter Call and Business Update. I would now turn the call over to Juli Miller.
- 11/08/2022
|
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
- Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2022, before the US markets open on Tuesday, November 8, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.
- 10/27/2022
|
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Tony Butler - Roth Anthony Rodriguez - Cowen & Company Jonathan Chang - SVP Leerink Mara Goldstein - Mizuho Securities Danya Hail - Jones Research Operator Good morning, everyone. Welcome to the Adaptimmune's Q2 Financial and Business Update Conference Call.
- 08/06/2022
|
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
- Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
- 07/01/2022
|
Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
- SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the treatment of patients with synovial sarcoma and MRCLS is expected in Q4 of 2022.
- 06/29/2022
|
Why Adaptimmune Therapeutics Stock Is Popping Today
- Buyout fever is sparking interest in the biotech's beaten-down shares today.
- 06/27/2022
|
Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
- Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell that targets the MAGE-A4 CTA and is being tried in multiple tumors types.
- 06/19/2022
|
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday
- The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.
- 05/17/2022
|
Adaptimmune Therapeutics' (ADAP) CEO Adrian Rawcliffe on Q1 2022 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Juli Miller – Head-Investor Relations Adrian Rawcliffe – Chief Executive Officer Gavin Wood – Chief Financial Officer Helen Tayton-Martin – Chief Business Officer John Lunger – Chief Patient Supply Officer Elliot Norry – Chief Medical Officer Cintia Piccina – Chief Commercial Officer Conference Call Participants Marc Frahm – Cowen and Company Tony Butler – ROTH Capital Faisal Khurshid – SVB Securities Nick Abbott – Wells Fargo Mara Goldstein – Mizuho Operator Good morning and thank you for standing by. Welcome to the First Quarter 2022 Adaptimmune Earnings Conference Call.
- 05/09/2022
|
New Strong Sell Stocks for April 26th
- ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
- 04/26/2022
|
New Strong Sell Stocks for April 22nd
- BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022
- 04/22/2022
|
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
- Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
- 04/19/2022
|
Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday
- Investors were not pleased that the company is preparing for a stock sale.
- 04/11/2022
|
New Strong Sell Stocks for April 11th
- DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2022.
- 04/11/2022
|
New Strong Sell Stocks for March 25th
- DDD, ADAP, and ADV have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2022.
- 03/25/2022
|
New Strong Sell Stocks for March 17th
- DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.
- 03/17/2022
|
Adaptimmune Therapeutics plc's (ADAP) CEO Adrian Rawcliffe on Q4 2021 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc's (ADAP) CEO Adrian Rawcliffe on Q4 2021 Results - Earnings Call Transcript
- 03/14/2022
|
Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022
- PHILADELPHIA and OXFORDSHIRE, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2021, before the US markets open on Monday, March 14, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:30 a.m. EDT (12:30 p.m. GMT) that same day (details below).
- 03/08/2022
|
Adaptimmune Therapeutics: A Little More Patience May Be Profitable
- I must say up front that I do not expect ADAP to make me a profit in the next 12 months because of the poor market conditions.
- 03/06/2022
|
After Plunging 19.1% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptimmune Therapeutics PLC (ADAP)
- The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 03/02/2022
|
4 Biotechs That Could Be Potential Takeover Targets in 2022
- We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
- 12/30/2021
|
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
- A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.
- 12/04/2021
|
Why Adaptimmune Therapeutics Stock Is Crashing Today
- Investor sentiment has turned against this promising cell therapy company.
- 12/01/2021
|
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
2 Biotech Companies That Might Be on Pfizer's Radar Right Now
- These two small-cap cancer companies would be a perfect fit for Pfizer.
- 11/04/2021
|
Adaptimmune Therapeutics: Q3 Earnings Insights
- Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
- 11/04/2021
|
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
- PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) that same day (details below).
- 10/21/2021
|
2 Top Healthcare Stocks That Could Be Bought Out in 2022
- These two novel-drug makers could be top takeover targets next year.
- 10/16/2021
|
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
- - Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -
- 10/05/2021
|
Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
- Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.
- 09/29/2021
|
Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?
- Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
- 09/24/2021
|
Why Adaptimmune Therapeutics Was Sinking This Week
- Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.
- 09/17/2021
|
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors and to express a CD8α co-receptor.
- 09/13/2021
|
ADAP Stock: Why It Increased Today
- The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased by over 10% pre-market today. This is why it happened.
- 09/13/2021
|
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
- - Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -
- 09/13/2021
|
Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies
- Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.
- 09/08/2021
|
ADAP Stock: 28.95% Increase Explanation
- The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased 28.95% today. This is why it happened.
- 09/07/2021
|
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
- A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.
- 09/07/2021
|
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic cell therapies for oncology indications. The collaboration includes developing allogeneic T-cell therapies for up to five shared cancer targets and personalized allogeneic T-cell therapies.
- 09/07/2021
|
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
- - Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform -
- 09/07/2021
|
Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate
- Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.
- 09/06/2021
|
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
- - One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff -
- 09/05/2021
|
Why Adaptimmune Therapeutics Stock Is Spiking Today
- The hunt for the next biotech buyout play is apparently underway.
- 08/23/2021
|
Implied Volatility Surging for Adaptimmune Therapeutics (ADAP) Stock Options
- Investors need to pay close attention to for Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
- 08/16/2021
|
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
- PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets close on Monday, August 9, 2021. Following the announcement, the Company will host a live teleconference and webcast at 4:30 p.m. EDT (9:30 p.m. BST) that same day (details below).
- 07/28/2021
|
Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021
- The biotech's shares have definitely lost their shine in 2021.
- 07/19/2021
|
Dollar General, HP, Johnson & Johnson and More Friday Afternoon Analyst Calls
- With the trading day more than halfway over, the markets were moving higher going into the weekend.
- 05/28/2021
|
Why Adaptimmune Therapeutics Crushed the Market Today
- A key pipeline drug performs well in a mid-stage clinical trial.
- 05/20/2021
|
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4). Data will be presented at the American Society of Clinical Oncology (ASCO) congress.
- 05/20/2021
|
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 Trial
- - Data will support BLA filing for afamitresgene autoleucel next year -
- 05/19/2021
|
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF) The data were presented at the American Society for Cell and Gene Therapy (ASGCT) meeting.
- 05/11/2021
|
First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
- - Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells -
- 05/11/2021
|
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call Transcript
- 05/07/2021
|
Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript
- Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
- - Outlined strategy to build integrated cell therapy company and the Company's “2-2-5-2” five-year core value drivers -
- 02/25/2021
|
Adaptimmune: Clear Leader In TCR Therapies Targeting Solid Tumors, Speculative Investment
- Immense potential, TCR therapy leader, but early stage. Science looks excellent with some proof of concept but risks, especially toxicity risks, abound.
- 12/10/2020
|
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
- - SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -
- 11/20/2020
|
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
- - Data support confidence in SPEARHEAD-1 as a registrational trial -
- 11/19/2020
|
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
- - Data support continued development of ADP-A2M4CD8 -
- 11/09/2020
|
2 Cancer Stocks That Could Make You Filthy Rich
- Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.
- 11/08/2020
|
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript
- Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Adaptimmune Reports Q3 Financial Results and Business Update
- - Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -
- 11/05/2020
|
Spear Phishing Market Overview With Detailed Analysis, Competitive Landscape, Forecast 2026 Cisco Systems Inc., Votiro Inc., Ironscales Ltd., Microsoft, Symantec Corporation
- Oct 09, 2020 (CDN Newswire via Comtex) --
To gain insightful analysis and to have comprehensive understanding of the Spear Phishing Market and its commercial...
- 10/09/2020
|
360 S9 Robot Vacuum Cleaner review: A perfect fit for small homes
- Keeping your floors clean is a real chore. But reliable robot vacuums like the 360 S9 can help out with that.
- 10/07/2020
|
Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
|
Stocks To Watch: Spotlight On Palo Alto Networks, Best Buy And Xpeng Motors
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/22/2020
|
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/15/2020
|
All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to Buy
- Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 08/11/2020
|
Announcing: Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Soared An Exciting 367% In The Last Year
- It might be of some concern to shareholders to see the Adaptimmune Therapeutics plc (NASDAQ:ADAP) share price down 14...
- 08/10/2020
|
Did The Underlying Business Drive Adaptimmune Therapeutics' (NASDAQ:ADAP) Lovely 367% Share Price Gain?
- Adaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders have seen the share price descend 14% over the month. But that...
- 08/10/2020
|
Canadian outdoor collective project misfires, offering lessons to other small cannabis growers
- Canadian cannabis grower Mark Spear had a plan: Form an outdoor cannabis collective with some like-minded farmers, raise capital through equity crowdfunding and start growing high-quality outdoor flower in the Ottawa Valley region.
- 08/07/2020
|
Mizuho Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP) - Markets
- Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a
- 08/06/2020
|
Adaptimmune Reports Q2 Financial Results and Business Update
- \- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -\- Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - \- Granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma -\- Completed public offering with net proceeds of approximately $244m; guidance confirmed: funded into 2022 -\- Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) -PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results and provided a business update for the second quarter ended June 30, 2020.“We reported responses in multiple solid tumor types during the second quarter of 2020 demonstrating the potential of SPEAR T‑cells to deliver benefit to people with cancer. We also raised capital, placing us in a solid financial position to continue executing on our strategic plans,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Despite the impact of the COVID-19 pandemic on the biotech industry, we made good progress in our preparations toward launching our first product in the US in 2022 for patients with sarcoma, whilst initiating and planning new Phase 2 clinical trials. However, as we enter the second half of the year, we expect COVID-19 to continue to have an impact and are monitoring this evolving situation closely.”PLANNED MILESTONES 2H 2020 * Update on ADP-A2AFP Phase 1 trial at the International Liver Congress to be held virtually from August 27 to 29 \- An oral presentation entitled “Data from the third dose cohort of an ongoing study with ADP‑A2AFP SPEAR T-cells” will be presented by Dr. Bruno Sangro of Clinica Universidad de Navarra \- A poster summarizing data from the first two cohorts of the ADP-A2AFP Phase 1 trial will be presented by Dr. Tim Meyer of University College London * Updates on dose escalation cohorts from the SURPASS trial at a medical conference * Durability and translational data from patients with synovial sarcoma from the ADP-A2M4 Phase 1 trial at a medical conference * Investor Day to be held on November 20, 2020 CLINICAL UPDATES * With timeline continuing to support 2022 launch in the US, enrollment in the Phase 2 SPEARHEAD-1 trial of ADP-A2M4, for patients with synovial sarcoma or myxoid / round cell liposarcoma (MRCLS), continues to progress * The evolving COVID-19 pandemic continues to have an impact on clinical trials varying site-by-site and among countries * Phase 1 trials (ADP-A2AFP, radiation sub-study, and SURPASS) continue and patients are being enrolled and treated * First site has been initiated and has started screening patients for the SPEARHEAD-2 Phase 2 clinical trial, combining ADP‑A2M4 with pembrolizumab for people with head and neck cancer * Protocol design for the Phase 2 trial with ADP-A2M4CD8 in gastroesophageal cancers has commenced and sites are being identified. The Company plans to initiate this trial in the first half of 2021PROGRESS TOWARD GOAL OF LAUNCHING ADP-A2M4 IN SARCOMA IN THE US IN 2022 * Granted access to PRIME regulatory support by the EMA further confirming the potential of ADP‑A2M4 to treat people with advanced sarcoma, along with the previously granted Orphan Drug Designation (ODD) in Europe, as well as the FDA’s ODD and Regenerative Medicine Advanced Therapy designationMANUFACTURING AND SUPPLY * The Company has focused on manufacturing SPEAR T-cells for patients in the SPEARHEAD-1 trial and increasing capacity to provide for all ongoing and planned trials * Scaling up personnel, manufacturing processes and IT systems, and optimizing space in our Navy Yard facility in preparation for commercial launch in sarcoma * Following receipt of a Certificate of GMP Compliance from the MHRA for its vector manufacturing operations in July, the Company began using lentiviral vector produced in-house at its dedicated manufacturing space within the Cell and Gene Therapy Catapult Manufacturing Centre at Stevenage, UK for select clinical trials FUNDING * Underwritten public offering closed on June 4, 2020 generating net proceeds of approximately $244 millionFinancial Results for the three and six month periods ended June 30, 2020 * Cash / liquidity position: As of June 30, 2020, Adaptimmune had cash and cash equivalents of $122.4 million and Total Liquidity1 of $419.0 million. * Revenue: Revenue for the three and six months ended June 30, 2020 was $0.5 million and $1.3 million, respectively, compared to $0.2 million for both of the same periods in 2019. The increase in revenue is mainly due to further development of the third target nominated by GSK under the GSK Collaboration and License Agreement. * Research and development (R&D) expenses: R&D expenses for the three and six months ended June 30, 2020 were $20.5 million and $41.7 million, respectively, compared to $25.5 million and $47.5 million for the same periods in 2019. The decreases in both periods are primarily due to lower development costs brought about by COVID-19 delays, a reduction in the average number of employees engaged in research and development, and in-process research and development costs of $2.0m in 2019 as a result of entering into a collaboration agreement with Alpine Immune Sciences, Inc. * General and administrative (G&A) expenses: G&A expenses for the three and six months ended June 30, 2020 were $10.3 million and $19.6 million, respectively, compared to $10.1 million and $21.9 million for the same periods in 2019. The decrease in the six months ended June 30, 2020 was primarily driven by reduced travel costs and share-based compensation expense, partially offset by an increase in costs associated with commercialization. We expect that our general and administrative expenses will increase in the future as we expand our operations and move towards commercial launch. * Other (expense) income, net: Other (expense) income, net for the three and six months ended June 30, 2020 was an expense of $0.7 million and income of $0.2 million, respectively, compared to expenses of $6.3 million and $0.8 million for the same periods in 2019. Other (expense) income, net primarily comprises unrealized foreign exchange movements, which fluctuate depending on exchange rates and the amount of foreign currency assets and liabilities. * Net loss: Net loss attributable to holders of the Company’s ordinary shares for the three and six months ended June 30, 2020 was $29.9 million and $58.0 million, respectively, and $(0.04) and $(0.07) per ordinary share, respectively, compared to $41.1 million and $68.5 million and $(0.07) and $(0.11) per ordinary share for the same periods in 2019. Financial guidanceThe Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into 2022, as further detailed in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020, to be filed with the Securities and Exchange Commission following this earnings release.Conference Call and Webcast Information The Company will host a live teleconference at 8:00 a.m. EDT (1:00 p.m. BST) today, August 6, 2020. The live webcast of the conference call will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at the same address. To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (5488705).About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.Total Liquidity (a non-GAAP financial measure) Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities. Each of these components appears separately in the condensed consolidated balance sheet. The U.S.
- 08/06/2020
|
U.S. Stock Futures Edge Higher, Gold Rallies
- Bull market in gold continued, sending prices over $2,000 a troy ounce for second day, while U.S. Treasury yields remained near this year’s lows.
- 08/05/2020
|
Treasury yields move higher as markets monitor stimulus talks
- U.S. government debt prices were lower Wednesday morning as lawmakers remain deadlocked over further stimulus.
- 08/05/2020
|
Europe Points Higher Ahead Of Busy Data Day, Gold Shines
- Market Overview Analysis by City Index (Fiona Cincotta) covering: GBP/USD, XAU/USD, Gold Futures, SPDR® Gold Shares. Read City Index (Fiona Cincotta)'s latest article on Investing.com
- 08/05/2020
|
Pale Blue Portfolio Review, May 18-July 31: 17 Buys, 2 Sells, 15.45% Gains
- The Pale Blue Portfolio gained 15.45% between May 18 and July 31. I slightly adjusted my purchasing strategy in July.
- 08/04/2020
|
Stock futures flat as investors await stimulus bill, more earnings
- The Dow Jones Industrial Average rose for its third straight day on Tuesday.
- 08/04/2020
|
Small-Business Hiring Casts a Dark Cloud Over Coming Jobs Report
- The decline in small-business hiring last month came as Covid-19 cases began to surge anew, especially in the South and West, prompting some states to pause or roll back reopenings.
- 08/04/2020
|
Adaptimmune Therapeutics (NASDAQ:ADAP) versus Voyager Therapeutics (NASDAQ:VYGR) Financial Comparison
- Adaptimmune Therapeutics (NASDAQ:ADAP) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. Analyst Ratings This is a breakdown of recent ratings and price targets for Adaptimmune Therapeutics […]
- 08/04/2020
|
Automatic Data Processing (NASDAQ:ADP) Rating Lowered to Strong Sell at Zacks Investment Research
- Zacks Investment Research cut shares of Automatic Data Processing (NASDAQ:ADP) from a hold rating to a strong sell rating in a research note issued to investors on Friday, Zacks.com reports. The brokerage currently has $112.00 price target on the business services provider’s stock. According to Zacks, “ADP faces significant competition in each of its product […]
- 08/04/2020
|
Hunting For Bargains In The Nasdaq 100
- Analysis of NASDAQ 100 yields 23 stocks trading below 200-Day SMA. Micron and Western Digital may have room to run in second half of CY 2020.
- 08/03/2020
|
Weekly Outlook: RBA and BoE Interest Rates, US Jobs In Focus
- Market Overview Analysis by JFD Team covering: Nikkei 225, Crude Oil WTI Futures, United States Oil Fund, LP. Read JFD Team's latest article on Investing.com
- 08/03/2020
|
AMG ADVANCED METALLURGICAL GROUP N.V. : Détachement de dividende intermédiaire | Zone bourse
|
Disney, T-Mobile, CVS, Activision Blizzard, and Other Stocks for Investors to Watch This Week
- Second-quarter earnings season continues with results from Disney, T-Mobile, Fox, ViacomCBS, and Clorox. Video-game makers Take-Two and Activision Blizzard also report. Plus, July jobs data.
- 08/02/2020
|
Allegiant Flies Above the Pack With Its Budget-Meets-Leisure Formula
- In a year in which airlines have gotten hammered by the pandemic, a carrier with ultralow costs and flexible scheduling takes the lead. Not that the flight may not get a little rough.
- 08/01/2020
|
ADP va "adapter en profondeur le projet de réaménagement de l'aéroport de Roissy-Charles de Gaulle"
- Frappé de plein fouet par la crise que traverse le transport aérien, ADP réduit ses coûts et ses investissements pour revenir dans le vert dès 2021. Le groupe veut réduire la masse salariale et préfère réduire les rémunérations plutôt que supprimer des postes. Confronté à une baisse du trafic qui sera longue, ADP va "adapter" le projet d'extension de l'aéroport qui passait notamment par la construction du terminal 4 d'une capacité de 40 millions de passagers par an.
- 07/30/2020
|
ADP (NASDAQ: ADP) Q4 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of ADP - ADP stock
- 07/29/2020
|
Introducing The Pale Blue Portfolio
- The Pale Blue Portfolio prioritizes corporate responsibility and growth at a reasonable price. It limits the investing universe to companies that receive at least an A grade from MSCI's ESG database.
- 07/29/2020
|
Le projet d'extension de l'aéroport de Roissy doit être "revu en profondeur", estime Djebbari
- Selon le ministre délégué aux Transports Jean-Baptiste Djebbari, la crise sanitaire, qui a provoqué un effondrement du trafic aérien, impose de revoir "en profondeur" le projet d'extension du terminal 4 de Roissy-Charles de Gaulle, par ailleurs critiqué sur le plan environnemental.
- 07/28/2020
|
SPEAR REIT LIMITED – Results Of The Annual General Meeting - SENS
- Sens announcement for SPEAR REIT LIMITED – Results Of The Annual General Meeting - SENS
- 07/24/2020
|
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
- PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for the treatment of synovial sarcoma. PRIME access provides enhanced scientific and regulatory support by the EMA to developers of medicines with the potential to significantly address unmet medical needs. “We are thrilled that the EMA has acknowledged the potential of ADP-A2M4 to address an unmet medical need for more effective treatment options for patients with advanced synovial sarcoma,” said Dennis Williams, PharmD, Adaptimmune’s Senior Vice President, Late Stage Development. “Access to the enhanced EMA support and guidance offered in the PRIME scheme will facilitate the development of ADP-A2M4 to ensure this important medicine reaches patients with sarcoma as early as possible.”Access to the PRIME initiative for ADP-A2M4 was granted based on clinical data from the Phase 1 trial demonstrating compelling efficacy and early promising durability, with tolerable safety in patients with synovial sarcoma. Based on these data the Company initiated the SPEARHEAD-1 trial with ADP-A2M4, enrolling people with advanced synovial sarcoma and myxoid/ round cell liposarcoma (MRCLS) at clinical sites in Canada, France, Spain, the United Kingdom, and the United States (US). The SPEARHEAD-1 trial is intended to support the registration of ADP‑A2M4 for the treatment of advanced synovial sarcoma and MRCLS.In recent months, the US Food and Drug Administration granted Orphan Drug Designation (ODD) to SPEAR T-cells targeting MAGE-A4 for the treatment of soft tissue sarcomas and Regenerative Medicine Advanced Therapy designation for the treatment of synovial sarcoma. In addition, The EMA’s Committee for Orphan Medicinal Products adopted a positive opinion for ODD for ADP-A2M4 for the treatment of soft tissue sarcomas.The PRIME program aims to optimize development plans and speed up evaluation of medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options. The PRIME designation is awarded by the EMA to promising medicines that target an unmet medical need. To be eligible and accepted for PRIME, a medicine must show potential to benefit patients with unmet medical needs based on early clinical data coupled with non-clinical data. Through the PRIME program, the EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency. The program is intended to optimize development plans and expedite the review and approval process so that these medicines may reach patients as early as possible.About Synovial Sarcoma Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. There are approximately 50 types of soft tissue sarcomas, including synovial sarcoma, which accounts for approximately 6% to 10% of all soft tissue sarcomas. There remains a large unmet medical need for synovial sarcoma, and approximately one-third of synovial sarcomas occur in childhood and the peak incidence is in the third decade of life. The most common locations for this cancer are the hip, knee, ankle, and shoulder.About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.Adaptimmune Contacts:Media Relations:Sébastien Desprez — VP, Communications and Investor Relations T: +44 1235 430 583 M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.comInvestor Relations:Juli P. Miller, Ph.D. — Senior Director, Investor Relations T: +1 215 825 9310 M: +1 215 460 8920 Juli.Miller@adaptimmune.com
- 07/23/2020
|
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
- PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The press release and the live webcast of the conference call will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at the same address.To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (5488705).About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.Adaptimmune Contacts:Media Relations:Sébastien Desprez — VP, Communications and Investor Relations T: +44 1235 430 583 M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.comInvestor Relations:Juli P. Miller, Ph.D. — Senior Director, Investor Relations T: +1 215 825 9310 M: +1 215 460 8920 Juli.Miller@adaptimmune.com
- 07/22/2020
|
Vident Investment Advisory LLC Makes New Investment in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)
- Vident Investment Advisory LLC acquired a new stake in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 140,529 shares of the biotechnology company’s stock, valued at approximately $1,406,000. Several other institutional investors […]
- 07/22/2020
|
Adaptimmune Therapeutics (NASDAQ:ADAP) Upgraded by Zacks Investment Research to “Buy”
- Zacks Investment Research upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $10.00 price objective on the biotechnology company’s stock. According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer […]
- 07/15/2020
|
Should You Buy Adaptimmune Therapeutics plc (ADAP)?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 07/05/2020
|
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Given Average Recommendation of “Buy” by Analysts
- Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts […]
- 07/03/2020
|
JonesTrading Reaffirms Their Buy Rating on T2 Biosystems (TTOO) - Markets
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on T2 Biosystems (TTOO – Research Report).
- 07/01/2020
|
Analysts Offer Insights on Healthcare Companies: Zogenix (NASDAQ: ZGNX) and Merck & Company (NYSE: MRK) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX
- 06/29/2020
|
Autolus Therapeutics (AUTL) Received its Third Buy in a Row - Markets
- After William Blair and Needham gave Autolus Therapeutics (NASDAQ: AUTL) a Buy rating last month, the company received another Buy,
- 06/25/2020
|
Neoleukin Therapeutics (NLTX) Receives a Buy from Mizuho Securities - Markets
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) yesterday and set a
- 06/24/2020
|
JonesTrading Initiates a Buy Rating on Curis (CRIS) - Markets
- JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Curis (CRIS – Research Report) today and set a
- 06/23/2020
|
Green Plate Special: Eat more lobster — this is the kind of ask we really like
- The lobster industry has been hit hard this year. Here's a recipe to help you do your bit to help them.
- 06/21/2020
|
Radio Foot Internationale - Le Café des sports
- Au sommaire du Café des sports: 1/ Coupe d’Italie, Naples vainqueur ! La ville en liesse. La victoire d’un entraîneur Gennaro Gattuso ?
- 06/19/2020
|
Autolus Therapeutics (AUTL) Receives a Buy from Mizuho Securities - Markets
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a
- 06/19/2020
|
A Few Top Charts
- Stocks Analysis by Harry Boxer covering: Bed Bath & Beyond Inc, Ballard Power Systems Inc, Apache Corporation, Arena Pharmaceuticals Inc. Read Harry Boxer's latest article on Investing.com
- 06/19/2020
|
Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (NYSE MKT: ARMP), BioMarin Pharmaceutical (NASDAQ: BMRN) and Trillium Therapeutics (NASDAQ: TRIL) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Armata Pharmaceuticals
- 06/18/2020
|
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).
- 06/17/2020
|
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry
- Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/17/2020
|
Analysts' Top Healthcare Picks: Albireo Pharma (ALBO), Monopar Therapeutics Inc (MNPR) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma
- 06/16/2020
|
Xconomy: GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
- GlaxoSmithKline's years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won a key first-line
- 06/13/2020
|
Is Adaptimmune Therapeutics a Buy?
- Cancer is one of the most challenging conditions for investigational therapies to target because malignant cells are frequently able to disguise themselves as healthy cells, thereby surpassing detection from the body's immune system. One biotech company that's gaining ground in this field is Adaptimmune Therapeutics (NASDAQ: ADAP), which has a variety of pipeline candidates under investigation for targeting 10 types of solid tumors. Wall Street seems to agree, as institutional investors own 14% of the company.
- 06/12/2020
|
Youngsters reap rewards for their kindness during lockdown
- As part of mental health awareness week and this year’s campaign of #bekind, TCR Tiverton Community Radio showcased children in the community who had showed kindness, caring and coping during the COVID-19 pandemic
- 06/10/2020
|
Arrowsic closes Sewall Pond Conservation Area due to heavy use amid pandemic
- The Arrowsic Board of Selectmen will review the decision at their bi-weekly meetings and vote to either open the conservation area or keep it closed.
- 06/10/2020
|
Why Adaptimmune Therapeutics Stock Crushed It in May
- Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage biotech, saw its shares gain an astounding 230% over the month of May, according to data from S&P; Global Market Intelligence. What appears to have gotten investors truly excited was the news that Adaptimmune's most advanced clinical candidate, ADP-A2M4, reportedly produced durable responses in patients with synovial sarcoma. Adaptimmune's overarching goal, in effect, is to launch ADP-A2M4 as a novel treatment for synovial sarcoma by 2022.
- 06/08/2020
|
Transformational Challenge Nuclear Reactor: Microreactor Built Using 3D Printing
- Scientists at the Department of Energy Manufacturing Demonstration Facility at Oak Ridge National Laboratory have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023. But their
- 06/07/2020
|
This Is Exactly the Wrong Time for Another High-Speed Train Boondoggle | National Review
- Today, the truly gullible are being lured by those with a new sales pitch: “Boy, have I got a high-speed rail line for you.”
- 06/05/2020
|
Gold Interests Point Northward on N. American Markets
- Jun 04, 2020 (Baystreet.ca via COMTEX) --
There's gold in "them, thar markets," as the old saw goes, and with tension in the world, gold stocks tend to...
- 06/04/2020
|
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
- Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”). Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters of their option to purchase additional ADSs at the public offering price. Adaptimmune intends to use the net proceeds from this offering to advance the development of its immunotherapies into and through clinical trials as well as for other general corporate purposes.
- 06/04/2020
|
Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
- CAMBRIDGE, Mass., June 4, 2020 /PRNewswire via COMTEX/ --
CAMBRIDGE, Mass., June 4, 2020 /PRNewswire/ -- Artax Biopharma, Inc., a biotechnology company...
- 06/04/2020
|
Gene-edited T cells to treat diabetes inch closer to clinical trials
- Scientists at Seattle Children’s Research Institute and the Benaroya Research Institute have engineered T cells that mimic the immunosuppressive properties of regulatory T cells—an approach that they say could potentially be used to treat autoimmune diseases such as Type 1 diabetes.
- 06/03/2020
|
6 Stocks To Watch: Arena Pharma, Baozun, NIO, Precigen, Sea Limited, Stratasys
- Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Extreme Networks Inc, DXC Technology Co, Compugen. Read Harry Boxer's latest article on Investing.com
- 06/03/2020
|
Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD
- Biopharma Adaptimmune Therapeutics (ADAP) has now announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11 per ADS.The stock is currently trading at $11.61, following a jaw-dropping 867% year-to-date rally. On the announcement of the public offering, ADAP sunk 10% in Monday’s pre-market trading, but subsequently ended the day up 5%.Adaptimmune has also granted the underwriters a 30-day option to purchase up to an additional 3,075,000 ADSs at the public offering price. The gross offering size for this offering is expected to be $225.5 million, excluding any exercise of the underwriters’ option to purchase additional ADSs.All ADSs in this offering are being sold by Adaptimmune, and the company will use the proceeds to advance the development of immunotherapies into and through clinical trials as well as for other general corporate purposes. The offering is expected to close on or about June 4, 2020, subject to customary closing conditions.On May 29, ADAP spiked 127% after reporting positive durability and efficacy data in synovial sarcoma at the American Society for Clinical Oncology (ASCO) Annual Meeting.“We are raising our PT on shares of ADAP to $9 from $3 driven off data presented at ASCO which demonstrated broader platform value for the company’s T-cell receptor (TCR)-T-cell platform technology as well as increased probability of success (POS) for the indication of synovial sarcoma (SS)” cheered Mizuho Securities analyst Mara Goldstein following the event. She now assigns a probability of success for this indication of 90%, up from 70%.Similarly, JonesTrading analyst Soumit Roy upgraded ADAP to buy with a new $15 price target, writing “Adaptimmune’s ASCO data alleviates our key concern – clear signs of expansion beyond synovial sarcoma into esophageal gastric junction (EGJ) cancer, head & neck cancer (HNC) and possibly NSCLC.”Overall, ADAP continues to hold a Moderate Buy analyst consensus, with 2 hold ratings vs 3 buy ratings. The average analyst price target currently stands at $8.50 (27% downside potential). (See ADAP stock analysis on TipRanks).Related News: AbbVie Teams Up With Jacobio To Develop Cancer Inhibitor Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Gilead Sinks 3% On New Remdesivir Data; Analysts Stay Sidelined More recent articles from Smarter Analyst: * Coupa Software Seeks To Raise $1.1 Billion From Debt Sale * Global Airlines Are Set To Lose $84.3 Billion In 2020, IATA Says * Merck’s Keytruda Fails To Meet Endpoints In Bladder Cancer Trial * Five Below Surges 11% After-Hours Despite Earnings Miss
- 06/02/2020
|
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?
- Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
- 06/02/2020
|
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
- Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,075,000 ADSs at the public offering price. The gross offering size for this offering is expected to be $225.5 million, excluding any exercise of the underwriters’ option to purchase additional ADSs.
- 06/02/2020
|
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?
- Stocks Analysis by Zacks Investment Research covering: Adaptimmune Therapeutics Plc. Read Zacks Investment Research's latest article on Investing.com
- 06/02/2020
|
Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today
- Last Friday, Adaptimmune's shares rocketed higher on the heels of a positive clinical update for its experimental T-cell therapy platform, which was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting.
- 06/01/2020
|
Party Time: Brokers Just Made Major Increases To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Earnings Forecasts
- Adaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders will have a reason to smile today, with the analysts making...
- 06/01/2020
|
Company News for June 1, 2020
- Companies in the news are: ADAP, BIG, YAMHF, CGNX
- 06/01/2020
|
Adaptimmune's stock tumbles after plans for public stock offering
- Shares of Adaptimmune Therapeutics PLC tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments said it planned a public offering of 12.5 million shares. That represents about 9.6% of the shares outstanding. The company also plans to grant the underwriters of the offering options to buy additional shares to cover overallotments. Cowen and SVB Leerink are the joint book-running managers. The stock has more than tripled (up 206%) over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has rallied 18.3% and the S&P; 500 has gained 3.1%.
- 06/01/2020
|
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
- Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price.
- 06/01/2020
|
Adaptimmune Spikes 127% Post-ASCO; Analyst Triples Price Target
- Shares in UK-based biopharma Adaptimmune (ADAP) spiked 127% in Friday’s trading, after the company reported positive durability and efficacy data in synovial sarcoma at the American Society for Clinical Oncology (ASCO) Annual Meeting.The data demonstrated durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial, ADAP announced. Dr David Hong spoke of a 50% response rate with inclusion of unconfirmed PR assessed after data cut-off. The ASCO presentation also described a new response in a patient with lung cancer, and a response in a patient with head and neck cancer.At the same time, Adaptimmune also announced new responses in the SURPASS trial, confirming the potential for SPEAR T‑cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. In the SURPASS trial, three patients have responded out of the first four treated with ADP-A2M4CD8, ADAP said.These data further support the rationale for two new Phase 2 trials – SPEARHEAD-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction (EGJ) cancer planned for 1H 2021.“We are raising our PT on shares of ADAP to $9 from $3 driven off data presented at ASCO which demonstrated broader platform value for the company’s T-cell receptor (TCR)-T-cell platform technology as well as increased probability of success (POS) for the indication of synovial sarcoma (SS)” cheered Mizuho Securities analyst Mara Goldstein following the presentation. She now assigns a probability of success for this indication of 90%, up from 70%.According to Goldstein, responses accumulating in other tumor types, while not conclusive, point to broader potential in solid tumors. However she “does not yet see a critical mass in responses to more comfortably assign greater value to new indications.” As a result, the analyst reiterates her hold rating on the stock but tripled her price target to $9. Given ADAP’s recent rally this now translates into downside potential of 19%.Meanwhile JonesTrading analyst Soumit Roy upgraded ADAP to buy from hold previously. He has a more bullish $15 price target on the stock, indicating further upside potential of 35%. Overall, ADAP continues to hold a Moderate Buy analyst consensus, with the Street evenly split between hold and buy. The average analyst price target currently stands at $10 (13% downside potential). (See ADAP stock analysis on TipRanks).Related News: BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Macy’s Spikes 15% After-Hours On New Financing Deal * Buckle Down Says Street, As Stitch Fix Sinks 7% Post-Print * Brazil’s XP Acquires Majority Stake In Fliper; Shares Spike 12% * Gilead Seeks Europe Remdesivir Approval; Three Analysts Reiterate Bullish Calls
- 06/01/2020
|
The Dow Slipped 18 Points Because Trump Pulled His Punches on China
- Stocks pared back losses Friday after President Donald Trump delivered a China-focused speech that was more restrained than expected. There was no talk of sanctions or raised tariffs on Chinese goods.
- 05/29/2020
|
Here's Why Adaptimmune Therapeutics Is Rocketing Higher Today
- Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.
- 05/29/2020
|
Traders Sift Through Virtual Cancer Meeting’s Winners and Losers
- (Bloomberg) -- Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical Oncology’s virtual annual meeting.Wall Street was quick to crown small-caps Adaptimmune Therapeutics Plc and Trillium Therapeutics Inc. as well as heavyweight AstraZeneca Plc among the early winners with shares rallying on the back of their respective updates. On the flip side, uninspiring results from Arvinas Inc.’s prostate cancer study and Aveo Pharmaceuticals Inc.’s kidney cancer trial drove investors to punish shares.Here’s a breakdown of some of ASCO’s biggest winners and losers:Adaptimmune TherapeuticsThe small developer of cell therapies more than doubled in Friday’s session after announcing updated early-stage results from a handful of trials in a range of cancer types. The company said its treatments drove responses in esophagogastric junction, lung, and head and neck cancer patients. Adaptimmune plans to start a mid-stage study of its therapy in esophagogastric junction cancer patients in the first half of next year.Trillium TherapeuticsThe hedge fund darling jumped as much as 21% after updated results for its early-stage study of TTI-622 showed a second patient responded to treatment with their cancer shrinking, providing further evidence that the drug could help patients with lymphoma that has progressed after trying previous therapies.Ladenburg Thalmann analyst Wangzhi Li wrote that the update showcased “excellent safety and surprising monotherapy activity” in the second patient. The 81-year-old patient’s response was classified as a partial response, but looked like it was almost a complete recovery with nearly 100% of the tumor reduced after eight weeks of follow-up.AstraZenecaShares of the pharmaceutical giant rallied as much as 3.4% in London after updates from a trio of key cancer drugs. The U.K. drugmaker said its blockbuster drug Tagrisso cut the risk of lung cancer death while studies of Imfinzi and Enhertu showed meaningful benefits for patients with small-cell lung cancer and gastric cancer.Autolus TherapeuticsAutolus was among the Nasdaq Biotechnology Index’s top performers Friday after announcing new data on its CAR-T cell therapy in patients with diffuse large B cell lymphoma. The updated results showed the medicine was well tolerated with no patients experiencing dose-limiting toxicity, and there were no treatment-related deaths.Aveo PharmaceuticalsAveo tumbled as much as 23%, the worst drop since early November, after late-stage results for its kidney cancer study showed its medicine didn’t extend lives longer than Bayer’s Nexavar. Aveo erased some of its loss after Baird raised its price target to a Street-high $24 from $15, saying the analysis removed an overhang on shares.ArvinasThe New Haven, Connecticut-based biopharma company sank 18% to make it the Nasdaq Biotech Index’s worst performer after updated results from its early-stage trial of ARV-110 in prostate cancer failed to excite investors. Just two of the 20 patients in the trial saw their PSA levels decline by 50% or more, missing many analyst expectations.MacroGenicsMacroGenics fell as much as 16% after releasing additional data for a trio of cancer drugs. Wall Street has been closely watching early data on MGD013 and MGC018 after bullish commentary from its management team earlier this month caused shares to triple.Allogene TherapeuticsShares of Allogene were little changed, erasing an initial drop, after updated results for its off-the-shelf CAR-T therapy showed a decline in patient benefit compared to an initial peek earlier this month. Twelve of 19 patients with blood cancer have responded to Allogene’s ALLO-501 in the “Alpha” study, including seven that had a complete response, the company said.Analysts had already started to debate whether the early-stage drug data that spurred Allogene to recored highs and a more than $6 billion valuation was warranted.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 05/29/2020
|
Adaptimmune Stock Doubles on Positive Cancer Drug Data
- The company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers.
- 05/29/2020
|
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
- - New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data.
- 05/29/2020
|
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
- Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
- 05/24/2020
|
Where Will Adaptimmune Be in 5 Years?
- Focused on using engineering cells to help the immune system recognize and fight cancer, the company made waves when it showed activity against solid tumors. The engineered T cells increase the immune system's ability to detect cancer cells and destroy them. This method of tweaking patients' own cells and then giving the cells back to them has led to two Food and Drug Administration (FDA) approved cell therapies: Yescarta from Gilead and Kymriah from Novartis.
- 05/19/2020
|
Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT
- Q1 2020 Adaptimmune Therapeutics PLC Earnings Call
- 05/15/2020
|
Adaptimmune Therapeutics PLC (ADAP) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP)Q1 2020 Earnings CallMay 14, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to the Adaptimmune Q1 2020 Earnings Conference Call.
- 05/14/2020
|
Recap: Adaptimmune Therapeutics Q1 Earnings
- Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.04), which beat the estimate of ($0.25).Revenue of $761,000 rose by 0.00% from the same period last year, which missed the estimate of $23,290,000.Outlook Adaptimmune Therapeutics hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 14, 2020View more earnings on ADAPTime: 08:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/4772jrtcTechnicals 52-week high: $6.0052-week low: $0.71Price action over last quarter: Up 27.07%Company Description Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.See more from Benzinga * Meredith: Q3 Earnings Insights * Wabash National: Q1 Earnings Insights * Recap: Aemetis Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/14/2020
|
Adaptimmune Reports Q1 Financial Results
- - Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug.
- 05/14/2020
|
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
- - Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for.
- 05/12/2020
|
What Kind Of Share Price Volatility Should You Expect For Adaptimmune Therapeutics plc (NASDAQ:ADAP)?
- If you own shares in Adaptimmune Therapeutics plc (NASDAQ:ADAP) then it's worth thinking about how it contributes to...
- 05/12/2020
|
Should coaches be paid for a canceled season?
- School districts in Maine have been wrestling with the dilemma, balancing financial concerns with the desire to reward coaches for work they do with student-athletes throughout the year.
- 05/10/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Volkswagen Golf GTI TCR: Pricing and arrival date announced
- After its reveal at the 2019 Festival of Motoring, Volkswagen South Africa has confirmed 300 units of the Golf GTi TCR will arrive towards the end of July.
- 05/03/2020
|
Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Corvus Pharmaceuticals (CRVS) yesterday and set a price target of $7.00. The company's
- 05/01/2020
|
Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Corvus Pharmaceuticals (
CRVS
–
Research Report
) yesterday and set a price target of
$7.00
. The company’s shares closed last Thursday at $2.43.
According to
TipRanks.com
, Goldstei
- 05/01/2020
|
Mizuho Securities Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (CTMX) today and set a price target of $16.00. The company's
- 04/29/2020
|
Mizuho Securities Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a
- 04/29/2020
|
BRIEF-Adaptimmune Therapeutics To Rely On SEC Order To Delay Filing Of Its Quarterly Report On Form 10-Q
- Adaptimmune Therapeutics PLC:
- 04/29/2020
|
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE) today and set a price target of $40.00. The company's shares
- 04/29/2020
|
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a
- 04/29/2020
|
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
- - The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP),.
- 04/29/2020
|
Citigroup Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $5.00
- Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective cut by analysts at Citigroup from $8.00 to $5.00 in a research note issued on Monday, BenzingaRatingsTable reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Citigroup‘s target price suggests a potential upside of 41.64% from the company’s current price. Several other equities research […]
- 04/29/2020
|
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock
- Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 04/28/2020
|
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock
- Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 04/28/2020
|
JonesTrading Sticks to Its Buy Rating for Deciphera Pharmaceuticals (DCPH)
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH). The company's shares closed last
- 04/28/2020
|
JonesTrading Sticks to Its Buy Rating for Deciphera Pharmaceuticals (DCPH)
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report).
- 04/28/2020
|
BRIEF-EMA Committee for Orphan Medicinal Products adopts positive opinion for Orphan Drug Designation for ADP-A2M4 -Adaptimmune Therapeutics
- Adaptimmune Therapeutics PLC:
- 04/28/2020
|
Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)
- Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK) today and set a price target of $100.00. The company's
- 04/28/2020
|
Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)
- Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK – Research Report) today and set
- 04/28/2020
|
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products
- Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas. Adaptimmune’s SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) is actively enrolling at approximately 25 clinical sites in Canada, France, Spain, the United Kingdom, and the US. The SPEARHEAD-1 trial is intended to support the registration of ADP‑A2M4 for the treatment of advanced synovial sarcoma and MRCLS.
- 04/28/2020
|
Why Did JonesTrading Downgrade Verastem's Stock?
- JonesTrading analyst Soumit Roy downgraded Verastem (VSTM) to Hold today. The company's shares closed last Monday at $2.12. According to TipRanks.com, Roy
- 04/27/2020
|
Why Did JonesTrading Downgrade Verastem’s Stock?
- JonesTrading analyst
Soumit Roy
downgraded Verastem (
VSTM
–
Research Report
) to
Hold
today. The company’s shares closed last Monday at $2.12.
According to
TipRanks.com
, Roy is a 4-star analyst with an average return of
10.4%
and a 37.4% success ra
- 04/27/2020
|
Mizuho Securities Believes Iovance Biotherapeutics (IOVA) Still Has Room to Grow
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Iovance Biotherapeutics (IOVA) today and set a price target of $61.00. The company's
- 04/27/2020
|
Mizuho Securities Believes Iovance Biotherapeutics (NASDAQ: IOVA) Still Has Room to Grow
- Mizuho Securities analyst
Mara Goldstein
reiterated a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) today and set a price target of
$61.00
. The company’s shares closed last Friday at $36.91, close to its 52-week high of $39.00.
Ac
- 04/27/2020
|
Merck & Company (MRK) Receives a Buy from Mizuho Securities
- In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK), with a price target of $100.00.
- 04/23/2020
|
Merck & Company (MRK) Receives a Buy from Mizuho Securities
- In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK –
- 04/23/2020
|
The Global T-Cell Immunotherapy Market is expected to grow from USD 33,923.13 Million in 2018 to USD 79,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.88%
- The positioning of the Global T-Cell Immunotherapy Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support
- 04/23/2020
|
Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Neutral Rating from Analysts at Mizuho
- Equities research analysts at Mizuho began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued on Tuesday, MarketBeat reports. The brokerage set a “neutral” rating and a $3.00 price target on the biotechnology company’s stock. Mizuho’s price target points to a potential downside of 11.50% from the company’s previous close. A number […]
- 04/23/2020
|
BofA likes Johnson & Johnson in premarket analyst action
- Adaptimmune (NASDAQ:ADAP) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities.Autolus Therapeutics (NASDAQ:AUTL) initiated with Buy rating and $18 (90% upside) p
- 04/22/2020
|
Adaptimmune Therapeutics (ADAP) Initiated with a Hold at Mizuho Securities
- Mizuho Securities analyst Mara Goldstein initiated coverage with a Hold rating on Adaptimmune Therapeutics (ADAP) today and set a price target of $3.00.
- 04/21/2020
|
Adaptimmune Therapeutics (ADAP) Initiated with a Hold at Mizuho Securities
- Mizuho Securities analyst
Mara Goldstein
initiated coverage with a
Hold
rating on Adaptimmune Therapeutics (
ADAP
–
Research Report
) today and set a price target of
$3.00
. The company’s shares closed last Tuesday at $3.62.
According to
TipRanks.com
- 04/21/2020
|
Autolus Therapeutics (AUTL) Receives a New Rating from Mizuho Securities
- In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL) and a price target
- 04/21/2020
|
Autolus Therapeutics (AUTL) Receives a New Rating from Mizuho Securities
- In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL
- 04/21/2020
|
Mizuho Securities Initiates a Buy Rating on Iovance Biotherapeutics (IOVA)
- In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Iovance Biotherapeutics (IOVA) and a price
- 04/21/2020
|
Mizuho Securities Initiates a Buy Rating on Iovance Biotherapeutics (IOVA)
- In a report released today,
Mara Goldstein
from Mizuho Securities initiated coverage with a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) and a price target of
$61.00
. The company’s shares closed last Tuesday at $36.63, close to i
- 04/21/2020
|
JonesTrading Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX) today and set a price target of $130.00. The company's shares closed
- 04/20/2020
|
JonesTrading Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
- JonesTrading analyst
Soumit Roy
reiterated a
Buy
rating on Mirati Therapeutics (
MRTX
–
Research Report
) today and set a price target of
$130.00
. The company’s shares closed last Monday at $93.79.
According to
TipRanks.com
, Roy is a 4-star analyst
- 04/20/2020
|
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Given Consensus Recommendation of "Buy" by Analysts
- Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has been given a consensus rating of “Buy” by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have […]
- 04/19/2020
|
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Short Interest Up 70.5% in March
- Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 708,600 shares, a growth of 70.5% from the March 15th total of 415,600 shares. Based on an average trading volume of 1,930,000 shares, the short-interest ratio […]
- 04/17/2020
|
JonesTrading Sticks to Their Buy Rating for Surface Oncology (SURF)
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF), with a price target of $12.00. The company's
- 04/16/2020
|
JonesTrading Sticks to Their Buy Rating for Surface Oncology (SURF)
- In a report released today,
Soumit Roy
from JonesTrading reiterated a
Buy
rating on Surface Oncology (
SURF
–
Research Report
), with a price target of
$12.00
. The company’s shares closed last Thursday at $2.72.
According to
TipRanks.com
, Roy is a
- 04/16/2020
|
Adaptimmune Therapeutics (NASDAQ:ADAP) Upgraded at BidaskClub
- Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Separately, Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Three analysts have rated the stock with […]
- 04/16/2020
|
2 Penny Stocks That Could Make You Rich
- Adaptimmune Therapeutics and OrganiGram Holdings are two penny stocks that may be worth the risk.
- 04/13/2020
|
Raymond James & Associates Grows Stock Position in Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
- Raymond James & Associates boosted its stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,411 shares of the biotechnology company’s stock after acquiring an additional 3,546 shares during the quarter. Raymond […]
- 04/13/2020
|
JonesTrading Thinks Aileron Therapeutics' Stock is Going to Recover
- JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company's
- 04/08/2020
|
JonesTrading Thinks Aileron Therapeutics’ Stock is Going to Recover
- JonesTrading analyst
Soumit Roy
initiated coverage with a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) today and set a price target of
$5.00
. The company’s shares closed last Tuesday at $0.32, close to its 52-week low of $0.25.
Acco
- 04/08/2020
|
Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March
- These three clinical-stage biotechs are all bargains after last month's marketwide downturn.
- 04/06/2020
|
Marshall Wace LLP Reduces Stock Holdings in Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
- Marshall Wace LLP lowered its position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 63.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,102 shares of the biotechnology company’s stock after selling 50,146 shares during the quarter. Marshall Wace LLP’s holdings in Adaptimmune […]
- 04/06/2020
|
Stocks To Watch: OPEC Goes Virtual
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 04/04/2020
|
JonesTrading Thinks Monopar Therapeutics Inc's Stock is Going to Recover
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR). The company's shares closed last
- 03/31/2020
|
JonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to Recover
- In a report released today,
Soumit Roy
from JonesTrading reiterated a
Buy
rating on Monopar Therapeutics Inc (
MNPR
–
Research Report
). The company’s shares closed last Monday at $7.09, close to its 52-week low of $4.95.
According to
TipRanks.com
,
- 03/31/2020
|
Zacks: Analysts Expect Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Will Post Quarterly Sales of $25.90 Million
- Wall Street brokerages expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to report sales of $25.90 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $50.30 million. The firm is […]
- 03/29/2020
|
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Short Interest Down 11.3% in March
- Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totalling 415,600 shares, a drop of 11.3% from the February 27th total of 468,800 shares. Based on an average daily trading volume, of 390,800 shares, the days-to-cover […]
- 03/28/2020
|
Vascular Biogenics (VBLT) Receives a Buy from JonesTrading
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Vascular Biogenics (VBLT), with a price target of $3.75. The company's
- 03/26/2020
|
Vascular Biogenics (VBLT) Receives a Buy from JonesTrading
- In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report),
- 03/26/2020
|
Celyad (CYAD) Received its Third Buy in a Row
- After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from JonesTrading.
- 03/25/2020
|
Celyad (CYAD) Received its Third Buy in a Row
- After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy,
- 03/25/2020
|
T2 Biosystems (TTOO) Gets a Buy Rating from JonesTrading
- JonesTrading analyst Soumit Roy reiterated a Buy rating on T2 Biosystems (TTOO) today and set a price target of $2.50. The company's shares closed last
- 03/25/2020
|
T2 Biosystems (TTOO) Gets a Buy Rating from JonesTrading
- JonesTrading analyst Soumit Roy reiterated a Buy rating on T2 Biosystems (TTOO – Research Report) today and set a price
- 03/25/2020
|
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Receives Consensus Recommendation of "Buy" from Brokerages
- Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has received a consensus rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that […]
- 03/25/2020
|
Top Pharma Stocks Under $5
- These clinical-stage drugmakers could be a steal at current levels.
- 03/24/2020
|
Edited Transcript of ADAP earnings conference call or presentation 27-Feb-20 1:00pm GMT
- Q4 2019 Adaptimmune Therapeutics PLC Earnings Call
- 03/21/2020
|
Vascular Biogenics (VBLT) Gets a Buy Rating from JonesTrading
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Vascular Biogenics (VBLT) today and set a price target of $3.75. The company's shares closed
- 03/19/2020
|
Vascular Biogenics (VBLT) Gets a Buy Rating from JonesTrading
- JonesTrading analyst
Soumit Roy
reiterated a
Buy
rating on Vascular Biogenics (
VBLT
–
Research Report
) today and set a price target of
$3.75
. The company’s shares closed last Monday at $0.95, close to its 52-week low of $0.90.
According to
TipRank
- 03/19/2020
|
Edited Transcript of ADAP earnings conference call or presentation 27-Feb-20 1:00pm GMT
- Q4 2019 Adaptimmune Therapeutics PLC Earnings Call
- 03/19/2020
|
Fastest VW Golf GTI revealed
- One of Australia’s most popular hot hatches is about to get a lot more performance.
- 03/16/2020
|
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Short Interest Update
- Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 468,800 shares, a decrease of 28.2% from the February 13th total of 653,000 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average daily trading […]
- 03/13/2020
|
Passage Bio's IPO tops out at $248.4M after options exercised
- Passage Bio Co-Founder Dr. James Wilson.
- 03/11/2020
|
JonesTrading Keeps a Buy Rating on Deciphera Pharmaceuticals (DCPH)
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH) today. The company's shares closed last Monday at $49.99.
- 03/11/2020
|
Cowen & Co. Sticks to Its Buy Rating for Constellation Pharmaceuticals (CNST)
- Cowen & Co. analyst Marc Frahm maintained a Buy rating on Constellation Pharmaceuticals (CNST) yesterday. The company's shares closed last Monday at
- 03/11/2020
|
Cowen & Co. Sticks to Its Buy Rating for Constellation Pharmaceuticals (CNST)
- Cowen & Co. analyst
Marc Frahm
maintained a
Buy
rating on Constellation Pharmaceuticals (
CNST
–
Research Report
) yesterday. The company’s shares closed last Monday at $32.41.
According to
TipRanks.com
, Frahm is a 3-star analyst with an average ret
- 03/11/2020
|
Surface Oncology (SURF) Gets a Buy Rating from JonesTrading
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Surface Oncology (SURF) today and set a price target of $12.00. The company's shares closed
- 03/09/2020
|
Surface Oncology (SURF) Gets a Buy Rating from JonesTrading
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Surface Oncology (SURF – Research Report) today and set a price
- 03/09/2020
|
Zacks Investment Research Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) to Hold
- Zacks Investment Research downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports. According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in […]
- 03/07/2020
|
Cellectis SA (CLLS) Received its Third Buy in a Row
- After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy, this time from JonesTrading.
- 03/05/2020
|
Cellectis SA (CLLS) Received its Third Buy in a Row
- After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy,
- 03/05/2020
|
JonesTrading Sticks to Their Buy Rating for Infinity Pharma (INFI)
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Infinity Pharma (INFI) today and set a price target of $3.50. The company's shares closed last
- 03/04/2020
|
JonesTrading Sticks to Their Buy Rating for Infinity Pharma (INFI)
- JonesTrading analyst Soumit Roy reiterated a Buy rating on Infinity Pharma (INFI – Research Report) today and set a price
- 03/04/2020
|
Sutura Therapeutics Appoints James Noble and Eduardo Bravo to Board of Directors
|
Analyst Explains Why They Downgraded Their Rating on Forty Seven (FTSV)
- Forty Seven (FTSV) received a Hold rating from JonesTrading analyst Soumit Roy today. The company's shares closed last Monday at $93.86, close to its
- 03/02/2020
|
